FBM is a new antiepileptic drug that has been administered as add-on therapy in 14 pediatric patients affected by drug-resistant partial or generalized epilepsies. FBM reduced significantly the total seizure frequency in 40% of subjects and it appear to be well tolerated. The improvement has persisted for up to 12 months.
|Translated title of the contribution||Felbamate as add-on in drug-resistant epilepsies of childhood|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1996|
ASJC Scopus subject areas
- Clinical Neurology